Biogen Inc. (BIIB) is a leading biotechnology company focused on discovering, developing, and delivering therapies for neurological, neurodegenerative, autoimmune, and rare diseases. Headquartered in Cambridge, Massachusetts, Biogen has established itself as one of the pioneers in neuroscience and is recognized for its expertise in treating complex diseases affecting the brain and nervous system.
Companies worth $10 billion or more are typically classified as “large-cap stocks,” and Biogen, with a market cap of $28.4 billion, fits the label perfectly. As one of the world's leading neuroscience-focused biotechnology companies, Biogen aims to drive long-term growth by leveraging its expertise in brain science, advancing innovative therapies, and expanding into adjacent areas of unmet medical need.
